APA (7th ed.) Citation

Zhanjing Dai, Jiayi Xu, Feng Chang, Wanxin Zhou, Ting Ren, Jiaxin Qiu, . . . Yuqiong Lu. (2024). The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Zhanjing Dai, Jiayi Xu, Feng Chang, Wanxin Zhou, Ting Ren, Jiaxin Qiu, Yun Lu, and Yuqiong Lu. The Cost-effectiveness of Iruplinalkib Versus Alectinib in Anaplastic Lymphoma Kinase-positive Crizotinib-resistant Advanced Non-small-cell Lung Cancer Patients in China. Frontiers Media S.A., 2024.

MLA (9th ed.) Citation

Zhanjing Dai, et al. The Cost-effectiveness of Iruplinalkib Versus Alectinib in Anaplastic Lymphoma Kinase-positive Crizotinib-resistant Advanced Non-small-cell Lung Cancer Patients in China. Frontiers Media S.A., 2024.